← Back to Search

Magnetic Lymph Node Mapping for Stomach Cancer

Phase 1
Waitlist Available
Led By Naruhiko Ikoma
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 or older
Pathologic diagnosis of gastric adenocarcinoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 24 hours of the ferrotrace injection
Awards & highlights

Study Summary

This trial is testing a new way to find cancer spread in the lymph nodes of people with gastric cancer. They will be using a magnetic tracer and a fluorescent dye. If it is effective, this could help researchers better detect the disease.

Who is the study for?
This trial is for adults with biopsy-proven gastric cancer, planning to undergo surgery (gastrectomy), without cancer spread beyond the stomach. Participants must consent and have a tumor size of 4 cm or less. It's not for those allergic to iron oxide or iodides, with iron overload disorders, pregnant or breastfeeding women.Check my eligibility
What is being tested?
The study tests FerroTrace (a magnetic tracer) combined with indocyanine green dye during gastrectomy in gastric cancer patients. This combo aims to better identify lymph nodes where cancer might have spread, potentially improving disease detection.See study design
What are the potential side effects?
Possible side effects may include reactions to the magnetic tracer or dye such as allergies, skin discoloration at injection site, and general discomfort. Since this is an investigational procedure, there may be unknown risks involved.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with stomach cancer.
Select...
I have gastric cancer confirmed by biopsy and am having surgery to remove it.
Select...
My cancer has not spread to distant parts of my body.
Select...
My stomach cancer is 4 cm or smaller, as measured before treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 24 hours of the ferrotrace injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 24 hours of the ferrotrace injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of endoscopic peritumoral gastric injection of FerroTrace

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort II (intraoperative)Experimental Treatment3 Interventions
Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.
Group II: Cohort I (preoperative injection)Experimental Treatment3 Interventions
Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indocyanine Green
2008
Completed Phase 2
~1050
Gastrectomy
2017
Completed Phase 2
~1330

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,958 Previous Clinical Trials
1,798,429 Total Patients Enrolled
Naruhiko IkomaPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Iron Conjugated Polymers in Saline Suspension Clinical Trial Eligibility Overview. Trial Name: NCT05038098 — Phase 1
Stomach Cancer Research Study Groups: Cohort II (intraoperative), Cohort I (preoperative injection)
Stomach Cancer Clinical Trial 2023: Iron Conjugated Polymers in Saline Suspension Highlights & Side Effects. Trial Name: NCT05038098 — Phase 1
Iron Conjugated Polymers in Saline Suspension 2023 Treatment Timeline for Medical Study. Trial Name: NCT05038098 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently engaged in this clinical experiment?

"At this time, registration for the trial has been closed. The protocol was initially posted on October 1st 2022 and last amended in September of that same year. If you are seeking alternative studies to participate in, 1174 clinical trials connected to gastric cancer and 30 Iron Conjugated Polymer in Saline Suspension programs currently need participants."

Answered by AI

Are recruitment efforts still underway for this research?

"Unfortunately, this clinical trial has ceased taking enrolments as of September 1st 2022. At present, 1174 studies are recruiting for patients with gastric cancer and another 30 trials require participants to test Iron Conjugated Polymers in Saline Suspension."

Answered by AI

How perilous is Iron Conjugated Polymer in Saline Suspension for patient consumption?

"Considering the limited data on efficacy and safety, Iron Conjugated Polymers in Saline Suspension is assigned a score of 1. This assessment comes from our team at Power since this is only a Phase 1 trial."

Answered by AI
~13 spots leftby Feb 2027